The website domain reflects its role for my own purpose only. Viewing of the webpages by others is not approved.
Site Developments
Main Index
ref: 20250816001.txt
Chapter 9
Will Asymptomatic and Moderate Aortic Stenosis Trials Change Timing of Intervention?
Key Trials and Findings
1. EARLY TAVR Trial
Design: Randomized 901 asymptomatic patients with severe AS to early TAVR vs. surveillance.
Findings: Early TAVR reduced death, stroke, or unplanned cardiovascular hospitalization (26.8% vs. 45.3%).
Implication: Supports early intervention in asymptomatic patients.
Reference: Généreux P, et al.
EARLY TAVR
.
NCT03042104
2. AVATAR Trial
Design: Randomized 157 asymptomatic patients with severe AS to early SAVR vs. conservative management.
Findings: Early SAVR reduced death, MI, stroke, or heart failure hospitalization (HR 0.46, p=0.02).
Implication: Strong evidence for early surgical intervention.
Reference: Banovic M, et al.
Circulation
. 2022;145(9):648–658.
NCT02436655
3. EVOLVED Trial
Design: Focused on asymptomatic patients with myocardial fibrosis (LGE on CMR).
Findings: No significant difference in death or AS-related hospitalization; improved NYHA class with early AVR.
Implication: Fibrosis-based risk stratification may not yet guide early intervention.
Reference: Loganath K, et al.
JAMA
. 2025;333(3):213–221.
NCT03094143
Expert Perspectives and Meta-Analyses
Meta-analysis of four RCTs showed lower stroke, heart failure hospitalization, and unplanned cardiovascular hospitalizations with early intervention.
Many "asymptomatic" patients are misclassified; stress testing reveals symptoms in up to 40%.
Registry data show delayed intervention leads to poorer outcomes.
Reference: Gahl B, et al.
JAMA Cardiology
. 2020;5(10):1102–1112.
DOI
Guideline and Expert Commentary
Current guidelines recommend AVR in asymptomatic patients only under specific conditions.
New trial data challenge this, suggesting routine early AVR may be beneficial.
Experts propose shifting from “watchful waiting” to “proactive intervention.”
Reference: Nishimura RA, O’Gara PT, Bonow RO.
JAMA Cardiology
. 2025;10(6):523–524.
DOI
Conclusion
Recent trials favor earlier treatment to prevent adverse outcomes.
Paradigm shift in guidelines and clinical practice may be imminent.
Emphasis on early identification and timely referral to heart valve teams.
ref:2025081503